← ANALYST RATINGS · TIPRANKS
Novo Nordisk (NVO): analyst forecast and price target
Analyst consensus
Hold0 Buy3 Hold1 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $42.33, the highest $47.00, the lowest $40.00. The average is +9.0% from the last price of $38.83.
Analyst ratings 13
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Kerry Holford★★★★★★★★★★#2798 · hits 58% · avg +8.7% | Berenberg Bank | $47.00 | Hold | +21.0% | Reiterated | 13.10.26on TipRanks Oct 14 09:50 | −1.3%next day +1.2% | ↗ |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $47.00 → $40.00−14.9% | Hold | +3.0% | Reiterated | 12.10.26on TipRanks 08:55 | −0.1%next day −1.3% | ↗ |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $47.00 | Hold | +21.0% | Reiterated | 07.10.26on TipRanks 08:35 | +2.2%next day +0.2% · 5 days +0.6% | ↗ |
| AI xAi Drug Manufacturers - GeneralxAI Grok-3 | TipRanks - xAI | $45.00 → $42.00−6.7% | Buy | +8.2% | Reiterated | 02.10.26on TipRanks 11:05 | — | |
| AI DeepSeek Drug Manufacturers - GeneralDeepSeek R1-0528 | TipRanks - DeepSeek | $45.00 → $42.00−6.7% | Buy | +8.2% | Reiterated | 02.10.26on TipRanks 11:05 | — | |
| AI OpenAI Drug Manufacturers - GeneralOpenAI 4o | TipRanks - OpenAI | $45.00 → $42.00−6.7% | Buy | +8.2% | Reiterated | 02.10.26on TipRanks 11:05 | — | |
| AI Anthropic Drug Manufacturers - GeneralAnthropic Opus-4.1 | TipRanks - Anthropic | $43.00 → $40.00−7.0% | Hold | +3.0% | Reiterated | 02.10.26on TipRanks 11:05 | — | |
| AI Google Drug Manufacturers - GeneralGemini 2.5Pro | TipRanks - Google | $45.00 → $42.00−6.7% | Buy | +8.2% | Reiterated | 02.10.26on TipRanks 11:05 | — | |
| AI PerPlexity Drug Manufacturers - GeneralPerPlexity SonarPro | TipRanks - PerPlexity | $46.00 → $43.00−6.5% | Buy | +10.7% | Reiterated | 02.10.26on TipRanks 11:05 | — | |
| Michael Nedelcovych★★★★★★★★★★#9548 · hits 48% · avg −1.2% | TD Cowen | $42.00 | Hold | +8.2% | Reiterated | 22.09.26on TipRanks Sep 23 02:30 | −1.0%next day −2.4% · 5 days −1.6% | ↗ |
| Unknown Analyst | Jefferies | $42.20 | Hold | +8.7% | Reiterated | 22.09.26on TipRanks 16:05 | −2.4%next day +1.3% · 5 days 0.0% | ↗ |
| Thibault Boutherin★★★★★★★★★★#3632 · hits 62% · avg +7.0% | Morgan Stanley | $40.00 | Sell | +3.0% | Downgrade | 11.09.26on TipRanks 04:50 | −3.0%next day +1.3% · 5 days +0.5% | ↗ |
| Kerry Holford★★★★★★★★★★#2798 · hits 58% · avg +8.7% | Berenberg Bank | $50.00 → $47.00−6.0% | Hold | +21.0% | Downgrade | 11.08.26on TipRanks Aug 12 02:10 | −0.9%next day −1.9% · 5 days −1.8% | ↗ |
| Jasper Hellweg★★★★★★★★★★#2291 · hits 57% · avg +7.4% | Argus Research | — | Hold | — | Reiterated | 07.08.26on TipRanks Aug 10 08:30 | +2.2%next day +1.0% · 5 days −3.3% | ↗ |
| James Quigley★★★★★★★★★★#11930 · hits 41% · avg −6.8% | Goldman Sachs | $48.00 → $44.00−8.3% | Hold | +13.3% | Reiterated | 06.08.26on TipRanks Aug 7 12:30 | +3.4%next day +2.2% · 5 days +0.4% | ↗ |
| Martin Brenoe★★★★★★★★★★#11004 · hits 33% · avg −16.4% | Nordea Markets | — | Hold | — | Downgrade | 24.02.26on TipRanks 05:10 | −3.4%next day −2.0% · 5 days −4.0% | ↗ |
| Emmanuel Papadakis★★★★★★★★★★#2736 · hits 53% · avg +3.9% | Deutsche Bank | — | Hold | — | Downgrade | 23.02.26on TipRanks 08:30 | −15.4%next day −3.4% · 5 days −5.3% | ↗ |
| Rajesh Kumar★★★★★★★★★★#1587 · hits 62% · avg +14.5% | HSBC | $47.00 → $54.00+14.9% | Hold | +39.1% | Reiterated | 10.12.25on TipRanks 07:00 | +5.1%next day +2.3% · 5 days −0.3% | ↗ |
| Richard Vosser★★★★★★★★★★#4454 · hits 49% · avg +2.0% | J.P. Morgan | — | Buy | — | Reiterated | 24.11.25on TipRanks 07:45 | −7.1%next day +3.7% · 5 days +3.6% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Novo Nordisk
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 07.10.26: target $43.70 at a price of $37.53 (+16.4%); now: $42.53 at $38.83 (+9.5%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Hold | 7 | 4 | 6 | 10 | 12 | 13 |
| Sell | 0 | 0 | 0 | 0 | 1 | 1 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.74 (from $0.68 to $0.89). Last quarter: $0.95.
Sales
Next quarter’s sales estimate — $11.2B (from $10.7B to $11.8B). Last quarter: $12.2B.
Best top-analyst consensus in the sector · Healthcare
About Novo Nordisk
- CEO: Maziar Mike Doustdar
- Employees: 68,794
- Novo Alle 1, Bagsvaerd, CR, 2880, DK
- www.novonordisk.com
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Data from the stock’s TipRanks forecast page, read 59 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗